The Role of HPV DNA Integration in Oncogenesis

Human Papillomavirus (HPV) is a small DNA virus. During a typical, transient infection, the viral genome exists as an episome—a separate, circular piece of DNA that replicates independently within the host cell's nucleus. However, a critical event in the progression from a benign infection to invasive cancer is the integration of the viral DNA directly into the host cell's chromosomes.

The Mechanics of Viral Integration

Integration occurs when the circular viral DNA breaks open and splices itself into the human genome. This event is not part of the normal viral life cycle; rather, it is an accident often triggered by genomic instability in the host cell, which may result from chronic inflammation or prolonged viral persistence. Integration frequently occurs at fragile sites within the host DNA.

Disruption of the E2 Regulatory Gene

When the viral episome breaks to integrate, the break almost always occurs within the E2 gene. The E2 protein is a crucial regulatory molecule that controls the expression of the viral oncogenes E6 and E7. When E2 is disrupted during integration, its suppressive control is lost. This leads to the massive, unregulated over-expression of E6 and E7.

The Action of E6 and E7 Oncoproteins

The unregulated high levels of E6 and E7 proteins wreak havoc on the host cell's regulatory pathways, primarily targeting two critical tumor suppressor proteins:

• E6 targets p53: The p53 protein normally senses DNA damage and triggers apoptosis (programmed cell death) if the damage cannot be repaired. E6 binds to p53 and causes its degradation, allowing cells with severe genetic mutations to survive and proliferate.
• E7 targets pRb: The retinoblastoma protein (pRb) controls the cell cycle, preventing the cell from dividing prematurely. E7 binds to and inactivates pRb, forcing the cell into continuous, uncontrolled replication.

Clinical Implications

Viral integration is a definitive molecular marker of progression toward malignancy. While episomal HPV can cause low-grade cervical dysplasia (CIN 1), the high-grade lesions (CIN 2/3) and invasive carcinomas are strongly associated with integrated viral DNA. Understanding this process highlights why identifying specific HPV genotypes that are highly prone to integration (like HPV 16 and 18) is critical for clinical risk assessment.

An oncovirus or oncogenic virus is a virus that can cause cancer. This term originated from studies of acutely transforming retroviruses in the 1950–60s, when the term oncornaviruses was used to denote their RNA virus origin. With the letters RNA removed, it now refers to any virus with a DNA or RNA genome causing cancer and is synonymous with tumor virus or cancer virus.

The vast majority of human and animal viruses do not cause cancer, probably because of longstanding co-evolution between the virus and its host. Oncoviruses have been important not only in epidemiology, but also in investigations of cell cycle control mechanisms such as the retinoblastoma protein. The World Health Organization's International Agency for Research on Cancer estimated that in 2002, infection caused 17.8% of human cancers, with 11.9% caused by one of seven viruses.

A 2020 study of 2,658 samples from 38 different types of cancer found that 16% were associated with a virus. These cancers might be easily prevented through vaccination (e.g., papillomavirus vaccines), diagnosed with simple blood tests, and treated with less-toxic antiviral compounds. Generally, tumor viruses cause little or no disease after infection in their hosts, or cause non-neoplastic diseases such as acute hepatitis for hepatitis B virus or mononucleosis for Epstein–Barr virus.

A minority of persons (or animals) will go on to develop cancers after infection. This has complicated efforts to determine whether or not a given virus causes cancer. The well-known Koch's postulates, 19th-century constructs developed by Robert Koch to establish the likelihood that Bacillus anthracis will cause anthrax disease, are not applicable to viral diseases. Firstly, this is because viruses cannot truly be isolated in pure culture—even stringent isolation techniques cannot exclude undetected contaminating viruses with similar density characteristics, and viruses must be grown on cells.

Secondly, asymptomatic virus infection and carriage is the norm for most tumor viruses, which violates Koch's third principle. Relman and Fredericks have described the difficulties in applying Koch's postulates to virus-induced cancers. Finally, the host restriction for human viruses makes it unethical to experimentally transmit a suspected cancer virus. Other measures, such as A. B. Hill's criteria, are more relevant to cancer virology but also have some limitations in determining causality.

Tumor viruses come in a variety of forms: Viruses with a DNA genome, such as adenovirus, and viruses with an RNA genome, like the hepatitis C virus (HCV), can cause cancers, as can retroviruses having both DNA and RNA genomes (Human T-lymphotropic virus and hepatitis B virus, which normally replicates as a mixed double and single-stranded DNA virus but also has a retroviral replication component).

In many cases, tumor viruses do not cause cancer in their native hosts but only in dead-end species. For example, adenoviruses do not cause cancer in humans but are instead responsible for colds, conjunctivitis and other acute illnesses. They only become tumorigenic when infected into certain rodent species, such as Syrian hamsters. Some viruses are tumorigenic when they infect a cell and persist as circular episomes or plasmids, replicating separately from host cell DNA (Epstein–Barr virus and Kaposi's sarcoma-associated herpesvirus).

Other viruses are only carcinogenic when they integrate into the host cell genome as part of a biological accident, such as polyomaviruses and papillomaviruses. A direct oncogenic viral mechanism involves either insertion of additional viral oncogenic genes into the host cell or to enhance already existing oncogenic genes (proto-oncogenes) in the genome. For example, it has been shown that vFLIP and vCyclin interfere with the TGF-β signaling pathway indirectly by inducing oncogenic host mir17-92 cluster.

Acquiring or enhancing oncogenecity can be evolutionarily favorable to the virus because increasing cell proliferation tends to also increase viral load. Indirect viral oncogenicity involves chronic nonspecific inflammation occurring over decades of infection, as is the case for HCV-induced liver cancer. These two mechanisms differ in their biology and epidemiology: direct tumor viruses must have at least one virus copy in every tumor cell expressing at least one protein or RNA that is causing the cell to become cancerous.

Because foreign virus antigens are expressed in these tumors, persons who are immunosuppressed such as AIDS or transplant patients are at higher risk for these types of cancers. Chronic indirect tumor viruses, on the other hand, can be lost (at least theoretically) from a mature tumor that has accumulated sufficient mutations and growth conditions (hyperplasia) from the chronic inflammation of viral infection.

In this latter case, it is controversial but at least theoretically possible that an indirect tumor virus could undergo "hit-and-run" and so the virus would be lost from the clinically diagnosed tumor. In practical terms, this is an uncommon occurrence if it does occur. DNA oncoviruses typically impair two families of tumor suppressor proteins: tumor proteins p53 and the retinoblastoma proteins (Rb).

It is evolutionarily advantageous for viruses to inactivate p53 because p53 can trigger cell cycle arrest or apoptosis in infected cells when the virus attempts to replicate its DNA. Similarly, Rb proteins regulate many essential cell functions, including but not limited to a crucial cell cycle checkpoint, making them a target for viruses attempting to interrupt regular cell function. While several DNA oncoviruses have been discovered, three have been studied extensively.

Adenoviruses can lead to tumors in rodent models but do not cause cancer in humans; however, they have been exploited as delivery vehicles in gene therapy for diseases such as cystic fibrosis and cancer. Simian virus 40 (SV40), a polyomavirus, can cause tumors in rodent models but is not oncogenic in humans.

Frequently Asked Questions

Related Topics